Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
ONCOLOGY RESEARCH AND TREATMENT(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要